Search

Your search keyword '"Peng, Weiyi"' showing total 363 results

Search Constraints

Start Over You searched for: Author "Peng, Weiyi" Remove constraint Author: "Peng, Weiyi"
363 results on '"Peng, Weiyi"'

Search Results

5. A novel retinoic acid receptor-γ agonist antagonizes immune checkpoint resistance in lung cancers by altering the tumor immune microenvironment

6. Faslpr gene dosage tunes the extent of lymphoproliferation and T cell differentiation in lupus

7. Multiplatform Analysis of Intratumoral PTEN Heterogeneity in Melanoma

8. Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profiles

10. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity

12. Melanoma and immunotherapy bridge 2015

13. PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition

14. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy

15. 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer

17. FASlprgene dosage tunes the extent of lymphoproliferation and T cell differentiation in lupus

18. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer

19. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy

24. Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

25. Abstract 4444: Targeting PI3K isoforms to improve the effectiveness of T cell mediated immunotherapy

26. Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

27. Data from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

28. Abstract 1836: Combining a novel retinoic acid receptor-γ agonist with immune checkpoint blockade represses lung cancer growth in vivo

29. Supplementary Tables from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies

30. Supplementary Figures from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies

31. Supplementary Table S1 from CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

32. Data from CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

33. Supplementary Methods; Figures S1 - S22; Tables S2, S6, S9 - S12 from CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

34. Supplementary Methods, Figure Legends, Tables S1 - S3 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

35. Supplementary Figure S7 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

36. Supplementary Methods from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies

37. Data from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

38. Supplementary Tables 1 and 6-8 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

39. Supplementary Figure S2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

40. Supplementary Figure 3 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

41. Supplementary Figure 1 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

42. Figures S1-S9 from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression

44. Supplementary Figure 2 from BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

45. Supplementary Figure 9 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

46. Supplementary Figure Legend from BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

47. Supplementary Figure 7 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

48. Supplementary Figure Legend from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

49. Supplementary Figure 5 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

50. Supplementary information from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression

Catalog

Books, media, physical & digital resources